Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

Background & Aims: The investigational first-generation core inhibitor vebicorvir (VBR) demonstrated safety and antiviral activity over 24 weeks in two phase IIa studies in patients with chronic HBV infection. In this long-term extension study, patients received open-label VBR with nucleos(t...

Full description

Bibliographic Details
Main Authors: Man-Fung Yuen, Scott Fung, Xiaoli Ma, Tuan T. Nguyen, Tarek Hassanein, Hie-Won Hann, Magdy Elkhashab, Ronald G. Nahass, James S. Park, Ira M. Jacobson, Walid S. Ayoub, Steven-Huy Han, Edward J. Gane, Katie Zomorodi, Ran Yan, Julie Ma, Steven J. Knox, Luisa M. Stamm, Maurizio Bonacini, Frank Weilert, Alnoor Ramji, Michael Bennett, Natarajan Ravendhran, Sing Chan, Douglas T. Dieterich, Paul Yien Kwo, Eugene R. Schiff, Ho S. Bae, Jacob Lalezari, Kosh Agarwal, Mark S. Sulkowski
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:JHEP Reports
Subjects:
Hepatitis
Core inhibitor
Antiviral
Off-treatment
Open-label
Nucleos(t)ide reverse transcriptase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923003300

Internet

http://www.sciencedirect.com/science/article/pii/S2589555923003300

Similar Items